Axogen Inc. recently provided an update highlighting its strategic priorities and market opportunities in peripheral nerve care. The company emphasized a large and underserved U.S. nerve care market, noting that more than 1.5 million peripheral nerve injuries require treatment annually in its focus markets, including extremities, breast reconstruction, oral and maxillofacial, and prostate surgery. Axogen outlined a 2025-2028 plan targeting 15-20% compound annual growth, expansion in elective and planned procedures, and further development in the prostate surgery market. The company also detailed efforts to expand its commercial infrastructure, optimize business processes, generate high-level clinical evidence to support standard of care adoption, and advance product innovation. Axogen’s portfolio includes AVANCE®, the only FDA-approved biologic nerve scaffold, and supporting products used in over 200,000 patients. The presentation also addressed ongoing challenges such as the need for standardized care guidelines, increased awareness among surgeons and patients, improved referral pathways, and broader insurance coverage. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axogen Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.